AOD-9604 vs Sermorelin
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: GH fragment lipolysis research independent of GH axis stimulation vs. GH deficiency or GH stimulation research where FDA-reviewed human data and pulsatile GH release are .
Quick Answers
Which is better, AOD-9604 or Sermorelin?
Neither compound has a universal evidence advantage. Research distinction: GH fragment lipolysis research independent of GH axis stimulation vs. GH deficiency or GH stimulation research where FDA-reviewed human data and pulsatile GH release are .
What is the key difference between AOD-9604 and Sermorelin?
Sermorelin stimulates endogenous GH release from the pituitary; AOD-9604 is a GH fragment designed for direct metabolic effects without GH elevation - upstream GH stimulation vs. downstream GH-derived fragment.
Evidence Comparison
Sermorelin: FDA approved (later withdrawn commercially 2008), adult GH deficiency RCT data (Walker et al. 1997), 6-month human efficacy data. AOD-9604: negative Phase 3 obesity data. Sermorelin has a positive human efficacy track record; AOD-9604 does not.
Evidence Context Favoring AOD-9604
GH fragment lipolysis research independent of GH axis stimulation.
Evidence Context Favoring Sermorelin
GH deficiency or GH stimulation research where FDA-reviewed human data and pulsatile GH release are important.
Side-by-Side Snapshot
| Evidence grade | AOD-9604: Level D Sermorelin: Level B |
|---|---|
| Research status | AOD-9604: Preclinical Sermorelin: Historical FDA Approval |
| Primary category | AOD-9604: Weight Loss & Metabolic Sermorelin: Growth Hormone |
| Cited studies | AOD-9604: 2 Sermorelin: 2 |